8-K: Artelo Biosciences Adjourns Annual Meeting, Adds Auditor Vote

Artelo Biosciences, Inc. adjourned its 2025 annual meeting due to insufficient quorum and will reconvene on January 30, 2026, with an added proposal to ratify its independent auditor.

Summary

• Artelo Biosciences, Inc. (the Company) convened and then adjourned its 2025 annual meeting of stockholders on December 31, 2025, without conducting any business.
• The adjournment was due to insufficient votes to constitute a quorum.
• The Annual Meeting will reconvene at 8:00 a.m., Pacific Time, on Friday, January 30, 2026, and will still be held virtually via live audio webcast.
• An additional proposal to ratify the appointment of Malone Bailey LLP as the independent auditor for the fiscal year ending December 31, 2026, is anticipated to be added to the proposals.
• Supplemental proxy materials describing the additional proposal will be filed with the SEC and mailed to stockholders, along with a revised proxy card.
• The record date for stockholders entitled to vote at the Annual Meeting remains December 10, 2025.
• Proxies previously submitted will be voted at the reconvened Annual Meeting unless properly revoked, and stockholders who have already submitted a proxy or otherwise voted need not take any further action.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the adjournment of the annual meeting caused by a lack of quorum, which suggests administrative inefficiency or low shareholder engagement. However, the issue is procedural and has a clear resolution path with a reconvened meeting and an additional, routine proposal.

Negatives

• The 2025 annual meeting of stockholders was adjourned due to insufficient votes to constitute a quorum, indicating a potential challenge in achieving shareholder participation or engagement for critical votes.

Risks

• Future results, performance, or achievements may be materially different from any forward-looking statements due to known and unknown risks, uncertainties, and other factors.
• Such factors include those set forth in the Company's filings with the Securities and Exchange Commission.

Future Outlook

The 2025 annual meeting of stockholders is scheduled to reconvene on January 30, 2026, to provide stockholders with additional time to vote on the proposals. An additional proposal to ratify Malone Bailey LLP as the independent auditor for the fiscal year ending December 31, 2026, is anticipated to be added to the agenda.

Industry Context

This announcement is a procedural corporate governance update specific to Artelo Biosciences and does not directly reflect broader industry trends or competitive dynamics.

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the delay of the annual meeting and will need to consider an additional proposal regarding the independent auditor. Those who have not yet voted are encouraged to do so.

Next Steps

• File supplemental proxy materials with the SEC.
• Mail supplemental proxy materials and a revised proxy card to stockholders.
• Reconvene the 2025 annual meeting of stockholders on January 30, 2026.
• Stockholders to vote on proposals, including the anticipated ratification of Malone Bailey LLP as independent auditor.

Key Dates

Keywords

Artelo Biosciences, ARTL, Annual Meeting, Stockholders Meeting, Proxy Statement, Corporate Governance, Auditor Ratification, SEC Filing, 8-K